Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
In the framework of the preclinical validation of the hypoxic tracer [(18)F]EF3, a comparison was performed between uptake of [(18)F]EF3 and EF5 adducts detected by immunofluorescence in MCa-4, FSA, FSAII, Sa-NH and NFSA tumour-bearing mice. Mice were allowed to breath carbogen (5% CO(2), 95% O(2)), 21% oxygen or 10% oxygen. A significant correlation (r (2)=0.57; p<0.01) was found between the [(18)F]EF3 tumour-to-muscle ratio and the fluorescence intensity of EF5.
Mahy
P
P
Center for Molecular Imaging and Experimental Radiotherapy, Université Catholique de Louvain and St-Luc University Hospital, 10 Ave Hippocrate, 1200, Brussels, Belgium.
De Bast
M
M
Gillart
J
J
Labar
D
D
Grégoire
V
V
D000818:Animals; D015687:Cell Hypoxia; D004353:Drug Evaluation, Preclinical; D017341:Etanidazole / Q000031:analogs & derivatives* / Q000378:metabolism; D005354:Fibrosarcoma / Q000000981:diagnostic imaging* / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D006845:Hydrocarbons, Fluorinated / Q000378:metabolism*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging* / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D051379:Mice; D008809:Mice, Inbred C3H; D009593:Nitroimidazoles / Q000493:pharmacokinetics*; D009928:Organ Specificity; D010100:Oxygen / Q000378:metabolism*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014018:Tissue Distribution; D005466:Fluorocarbons
D017341:Etanidazole; D006845:Hydrocarbons, Fluorinated; D009593:Nitroimidazoles; D010100:Oxygen; D019275:Radiopharmaceuticals; C438056:2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide; C096011:2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; D005466:Fluorocarbons